A charting tool for estimating the PSA doubling time in patients with prostate cancer.

adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: Long-term results of the ARCOSEIN multicenter randomized study. Int J Radiat Oncol Biol Phys 2006;65:324–332. 2. Munshi A, Jalali R, Budrukar A. In regards to Arcangeli, et al. (Int J Radiat Oncol Biol Phys 2006;64:161–167). Int J Radiat Oncol Biol Phys 2006;65:632. 3. Arcangeli G, Pinnaro P, Rambone R, et al. A phase III randomized study on the sequence of radiotherapy and chemotherapy in the conservative management of early-stage breast cancer. Int J Radiat Oncol Biol Phys 2006;64:161–167. 4. Cowan JD, Neidhart J, McClure S, et al. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: A Southwest Oncology Group study. J Natl Cancer Inst 1991;83:1077–1084. 5. Isacson R, Safra T, Ben-Dor G. A preliminary report of a pilot randomised trial comparing cyclophosphamide, methotrexate and 5-fluorouracil with cyclophosphamide, mitoxantrone and 5-fluorouracil in the adjuvant therapy of stage II breast cancer with four or more positive axillary nodes. Anticancer Drugs 1993;4:189–192. 6. Recht A. Integration of systemic therapy and radiation therapy for patients with early-stage breast cancer treated with conservative surgery. Clin Breast Cancer 2003;4:104–113. 7. Rouëssé J, De la Lande B, Bertheault-Cvitkovic F, et al. A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: Final results. Int J Radiat Oncol Biol Phys 2006;64:1072–1080. 8. Hennequin C, Giocanti N, Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res 1996;56:1842–1850. 9. Burstein HJ, Bellon JR, Galper S, et al. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys 2006;64:496–504. 10. Prosnitz RG, Marks LB. Radiation-induced heart disease: Vigilance is still required. J Clin Oncol 2005;23:7391–7394.